<qa>  What is the primary outcome of the trial?This is a prospective, randomized, double-blind, placebo-controlled trial in which infertile women undergoing intrauterine insemination or embryo transfer are screened for BV prior to treatment. Those patients who screen positive for BV will then be randomized into the treatment armmetronidazole 500mg by mouth twice daily for 7 days or the control arm placebo by mouth twice daily for 7 days. The primary outcome, positive pregnancy test rate i.e. biochemical pregnancy rate, will then be assessed. Secondary outcomes, such as clinical pregnancy rate, miscarriage rate, and live birth rate will also be examined. 